inactivated influenza vaccine (split virion) bp, suspension for injection in prefilled syringe.influenza vaccine (split virion,
sanofi pasteur - a/michigan/45/2015 (h1n1)pdm09 - like strain (a/michigan/45/2015, nymc x-275); a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b); b/brisbane/60/2008 - like strain (b/brisbane/60/2008) - suspension for injection - 15/15/15mc percent volume/volume - influenza vaccines; influenza, inactivated, split virus or surface antigen
quadrivalent influenza vaccine (split virion, inactivated), suspension for injection in pre-filled syringe quadrivalent influenza vaccine (split virion, inactivated)
sanofi pasteur - a/victoria/4897/2022 (h1n1)pdm09-like strain (a/victoria/4897/2022, ivr-238; a/darwin/9/2021 (h3n2) - like strain (a/darwin/9/2021, ivr-228); b/austria/1359417/2021 - like strain (b/michigan/01/2021, wild type); b/phuket/3073/2013 -like strain (b/phuket/3073/2013, wild type) - suspension for injection in pre-filled syringe - 15 microgram(s) - influenza vaccines; influenza, inactivated, split virus or surface antigen
idflu
sanofi pasteur s.a. - influenza virus (inactivated, split) of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, wild type) - influenza, human; immunization - vaccines - prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.the use of idflu should be based on official recommendations.
intanza
sanofi pasteur europe - influenza virus (inactivated, split) of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, wild type) - influenza, human; immunization - vaccines - prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.the use of intanza should be based on official recommendations.
pumarix
glaxosmithkline biologicals s.a. - pandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) - influenza, human; immunization; disease outbreaks - vaccines - prophylaxis of influenza in an officially declared pandemic situation.pandemic-influenza vaccine should be used in accordance with official guidance.
fluarix tetra inactivated split influenza vaccine suspension for injection 0.5 ml pre-filled prtc syringe without needle, sh2024 influenza season
glaxosmithkline australia pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: dl-alpha-tocopheryl acid succinate; potassium chloride; sodium chloride; water for injections; polysorbate 80; dibasic sodium phosphate dodecahydrate; magnesium chloride hexahydrate; octoxinol 10; monobasic potassium phosphate - fluarix tetra is a quadrivalent vaccine indicated for active immunisation of adults and children from 6 months of age for the prevention of influenza disease caused by the influenza virus types a and b contained in the vaccine (see section 5.1 pharmacodynamic properties, clinical trials).,the use of fluarix tetra should be based on official recommendations.
fluquadri junior inactivated quadrivalent influenza vaccine (split virion), influenza virus haemagglutinin 30mcg, 0.25ml suspens
sanofi-aventis australia pty ltd - influenza virus haemagglutinin -
fluarix tetra inactivated split influenza vaccine suspension for injection 0.5 ml pre-filled syringe without needle, sh2024 influenza season
glaxosmithkline australia pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: dl-alpha-tocopheryl acid succinate; potassium chloride; sodium chloride; water for injections; polysorbate 80; dibasic sodium phosphate dodecahydrate; magnesium chloride hexahydrate; octoxinol 10; monobasic potassium phosphate - fluarix tetra is a quadrivalent vaccine indicated for active immunisation of adults and children from 6 months of age for the prevention of influenza disease caused by the influenza virus types a and b contained in the vaccine (see section 5.1 pharmacodynamic properties, clinical trials).,the use of fluarix tetra should be based on official recommendations.
panvax h1n1 vaccine junior h1n1 pandemic influenza vaccine (split-virion, inactivated) 0.25ml suspension for injection pre-filled syringe
seqirus pty ltd - influenza virus haemagglutinin, quantity: 7.5 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate - for active immunisation to prevent influenza disease caused by the influenza a (h1n1) virus, in persons from 6 months of age.
panvax h1n1 vaccine, h1n1 pandemic influenza vaccine (split-virion, inactivated) 5ml multi-dose injection vial
seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate; thiomersal - for active immunisation to prevent influenza disease caused by the influenza a (h1n1) virus, in persons from 6 months of age.